radionuclides and stereotactic body radiation therapy. These novel modalities have allowed for targeted therapy to specific parts of the body with minimal side efffects and high eradication potential.
Further, trials offering treatment with curative intent to patients with limited, 'oligometastatic' disease have shown promise Milano et al. [2009 Milano et al. [ , 2012 , although it is not yet possible to identify such patients in an objective manner Weichselbaum and Hellman [2011] .
Figure 1: Schematic of the human vascular system network topology. It is evident by inspection of the network diagram that tumors originating in the gut and lung experience significantly different flow patterns and a different order in which they experience filtration at capillary beds than tumors originating in other parts of the 'body' [Scott et al., 2012] . The alternate pathways (green) represent the fraction of cells which evade arrest (filtration) at a given capillary bed. There are scant measurements of this fraction in the literature, and none in clinical studies that evaluate outcomes. We postulate that by ascertaining the distribution of CTCs in this network for individual patients, information about the existence of subclinical metastatic disease, and therefore metastatic propensity, will come to light, and allow for better staging, prognostication and rational use of organ-directed therapy in the setting of oligometastatic disease.
In this letter we extend Weiss' method to understand metastatic proclivities of certain organ sites and to provide a framework by which to understand the metastatic distribution from novel CTC measurements. To do this, we consider blood flow between organs Williams and Leggett [1989] , filtration in capillary beds (see Figure 1 and Table 1 ) and distribution of metastatic involvement in a series of untreated patients at autopsy Disibio and French [2008] . For each organ-organ pair we calculate the MEI by normalising incidence by putative CTC flow between the two organs, taking into account the reduction that occurs in capillary beds Scott et al. [2012 Scott et al. [ , 2013 ; which has been shown to be of the order of 10 −4 cell −1 Okumura et al. [2009] . This post-capillary bed reduction in CTC numbers can be altered by the presence of micrometastases, which can amplify CTC numbers downstream of their location through shedding. Thus, by adjusting filtration rates throughout the network, we can represent any different configuration of metastatic disease and thus capture different organ-organ metastatic efficiencies.
To illustrate the effect of micrometastatic disease on MEIs, we compare four scenarios for a set of representative organ pairs: no micrometastases, micrometastases present in the lung, in the liver and in both locations (Figure 2 ). We see that Weiss' metric differs from ours, but more importantly that the metastatic efficiency depends on the current disease state. For example, our estimate of the efficiency with which cells orginating from a primary pancreatic tumor can form kidney metastases varies over six orders of magnitude, depending on whether micrometastatic lesions are present, and their location. This effect highlights an opportunity to go a step further in disease characterization than presence or absence of CTCs at staging.
The preceding analysis assumes that the filtration rate for each organ is identical for all patients in the data set. This is likely a gross oversimplification, but no clinical trial has yet determined the intrapatient heterogeneity in this (currently absent) parameter set. Previously we used incidence data to calculate MEIs, but we may also reverse the process and calculate the prevalence of micrometastatic disease given incidence data and organ-pair MEIs. Under this reasoning it is possible to show, for example, that the population incidence of metastases in the adrenal gland arising from primaries in the large intestine, which equals 7.5%, can be explained not only by a single patient group composition, but by a whole collection (see online methods). Indeed, the same argument can be made for any primary-metastasis pair: the population-level data tell us nothing about a given patient.
To enable these insights and their translation to the clinic, systematic testing of individual patient filter-flow parameters is required. Measurement of CTCs at initial staging and subsequent correlation with outcomes would yield initial model parameters with which rational prospective trials could be designed. This level of understanding of an individual patient's disease state constitutes a new type of personalized medicine, which seeks to assay not just the collection of mutations The impact of filter and flow characteristics on estimation of the metastatic efficienct index (MEI). We have compared Weiss' original method with our filter-flow framework under the assumption of no micrometastases, micrometastases in the lung, in the liver, and in both locations. The comparison is carried out for four organ pairs that cover the canonical pathways of spread (gut → body, body → body, lung → body and body → liver). We see that because Weiss' method only considers the dynamics on the arterial side it underestimates the MEI in two of the cases (pancreas → kidney, and bladder → liver). From the comparison it is also evident that assumptions about the presence or absence of micrometastases heavily influences the results, in the case of pancreas → kidney shifting the MEI six orders of magnitude from a low MEI to a high one (as defined by Weiss Weiss [1992] ).
that a patient's cancer cells have accumulated, but instead their physical location. This would allow for more accurate staging and the rational inclusion of organ directed therapy in clinical trials, a concept which is gaining popularity with recently approved methods existing for bone and liver [Harrison et al., 2013, Seront and Van den Eynde, 2012] .
By further elucidating the principles underlying hematogeonous metastasis, we hope to make inroads toward therapeutic strategy changes that would otherwise be impossible. Our results highlight the value of the physical perspective of the metastatic cascade, and the importance of addressing not only genetic factors, but also physiological and anatomical aspects of the process, which in this gene-centric era have been largely forgotten.
Online methods

Calculation of Metastatic Efficiency Index (MEI)
The autopsy dataset used in the analysis covers 3827 patients presenting with primary tumors in 30 different anatomical sites Disibio and French [2008] . For each primary tumor the number of metastases are reported according to anatomical site (in total 9484 metastases). As we focus on the effect of blood flow patterns, we consider only the organs for which blood flow has been measured, and this reduces the number of anatomical sites to 14 (detailed in Table 2 ).
For each organ-organ pair we calculate the metastatic involvement N ij as the ratio between the number of occurrences of the primary tumor in organ i and the number of metastases reported in the target organ j, for each pair (i, j) presented in the autopsy data Disibio and French [2008] .
We have that 0 ≤ N ij < 1 and this number corresponds to the fraction of cases where a primary tumor in organ i gave rise to a metastasis in organ j. The metastatic efficiency index (MEI) from organ i to j is then defined by M ij = N ij /φ ij , where φ ij is the relative flow of CTCs from organ i to j. This quantity takes into account the blood flow that each target organ receives (Table 1) and the reduction in CTCs that occurs en route between the two organs. For the sake of simplicity we consider only the effects of capillary bed passage, and it has been shown in clinical studies that approximately 1 in 10 000 CTCs remain viable after such a passage Okumura et al. [2009] . We thus assume that there occurs a reduction of CTC number by a factor F k when the cells pass through organ k. As a baseline, we use the pass rate F k = 10 −4 for all organs.
It is well known that metastases in the lung and liver have the ability to shed cells into the bloodstream and hence give rise to 'second order' metastases Bross et al. [1975] . If one were to measure the CTC concentration downstream of an organ containing metastases, then it would be higher than in the case of a disease-free organ. For our purposes, this implies that the presence of metastatic disease can be represented in the model as a lower reduction of CTCs in the capillary bed of the affected organ. This simplification is only valid if we disregard the biological properties of the CTCs (since CTCs originating from metastases might have different genotypes and phenotypes compared to cells from the primary tumor), but is sufficient for our purposes. To simulate the presence of micrometastases in the lung and liver we therefore change the pass rates to F L = 10 −1
and F H = 10 −1 respectively.
As an example of our methodology, we now present the calculations for the MEI for breast to adrenal gland. The cancer cells leaving a breast tumor enter the circulation on the venous side and are transported via the heart to the lung capillary bed, through which only a fraction F L pass as viable cells. These cells then flow into the arterial side of the circulation and are randomly distributed to the different organs of the body according to blood flow, of which the adrenal gland receives 0.3% (Table 1 ). The relative flow of CTCs from breast to adrenal gland is therefore given
Patient group decomposition
Although we calculated several distinct values of MEIs depending on the pattern of metastatic spread (presence of micrometastases), it is likely that most tumors originating in the same organ have roughly the same MEI, and that the presence of metastases in the liver and lung instead affect the incidence of secondary metastases. We now show how this can be used as a means to suggest possible patient group decompositions.
The incidence, N ij , relative flow of CTCs, φ ij and the MEI, M ij are related according to M ij = N ij /φ ij , or equivalently φ ij = N ij /M ij . We now assume that φ ij is not equal for all patients, and consider four patient groups: no micrometastases, micrometastases in the lung, micrometastases in the liver and micrometastases in both. If we now let n k denote the fraction of patients in each group, k, where n k = 1, then we can write
where φ k ij is the flow of CTCs in the different patient groups. This problem is underdetermined, and the solution (in terms of the fractions n i ) is given by any point on a surface defined by (1), such that n i > 0 for all patient groups and i n i = 1. This implies that aggregated incidence data can be explained by many different patient group compositions, each with its distinct pattern of metastatic progression.
The population incidence of metastases in the adrenal gland arising from primaries in the large intestine equals 7.5 %, and by fixing the MEI and using the above method, the incidence rate can be explained by a subdivision according to 25 % in the no metastasis group, 20 % in the liver metastases group, 5 % in the lung metastases group, and 50% of the patients harboring metastases in both liver and lung. However the incidence can also be explained by a subdivision of 5%, 25%, 20% and 50 % into each patient group respectively. This highlights the fact that population-based measures of incidence cannot be used to predict individual patient metastasis dynamics as different patients can exhibit fundamentally different patterns of spread. Williams and Leggett [1989] . The model compartment refers to the anatomical location of the organs and their relation to the circulatory system is shown in fig. 1 . 62  21  30  18  2  20  1  5  8  9  3  4  2  0  1  Pancreas  109  63  29  12  2  7  1  4  8  0  3  6  4  1  3  Skin  161  28  47  25  2  25  3  3 18 14 22 11 5  2 14  Small intestine  19  8  3  0  0  0  0  2  0  0  0  1  1  0  0  Stomach  477  146 84  45  7  39  2 13 14 44 11 25 3  0  5  Testes  25  19  18  6  0  8  0  2 11 3  2  3  2  1  2  Thyroid  43  10  22  4  0  6  0  0  1  3  4  1  0  0  0 
